Skip to content
10-Q

Quarterly Report

BICARA THERAPEUTICS INC. BCAX

0001628280-26-033429

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 65.7M sh
Shares Diluted Q1 2026 · Mar 31, 2026 60.72M sh
Shares Diluted Q1 2026 · Mar 31, 2025 54.46M sh
Capex Q1 2026 · Mar 31, 2026 $60K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$37.51M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$28.11M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $323.46M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $96.69M
Stockholders Equity Q1 2026 · Mar 31, 2026 $513.96M
Stockholders Equity Q1 2026 · Dec 31, 2025 $401.45M
Stockholders Equity Q1 2026 · Mar 31, 2025 $458.96M
Stockholders Equity Q1 2026 · Dec 31, 2024 $491.88M
Current Liabilities Q1 2026 · Mar 31, 2026 $39.34M
Current Liabilities Q1 2026 · Dec 31, 2025 $28.95M
Total Liabilities Q1 2026 · Mar 31, 2026 $39.64M
Total Liabilities Q1 2026 · Dec 31, 2025 $29.54M
Current Assets Q1 2026 · Mar 31, 2026 $544.92M
Current Assets Q1 2026 · Dec 31, 2025 $422.05M
Total Assets Q1 2026 · Mar 31, 2026 $553.6M
Total Assets Q1 2026 · Dec 31, 2025 $430.99M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.93
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.68
Eps Basic Q1 2026 · Mar 31, 2026 −$0.93
Eps Basic Q1 2026 · Mar 31, 2025 −$0.68
Sga Expense Q1 2026 · Mar 31, 2026 $12.74M
Sga Expense Q1 2026 · Mar 31, 2025 $7.46M
Net Income Q1 2026 · Mar 31, 2026 −$56.21M
Net Income Q1 2026 · Mar 31, 2025 −$36.85M
Operating Income Q1 2026 · Mar 31, 2026 −$60.24M
Operating Income Q1 2026 · Mar 31, 2025 −$41.79M